Seeking Alpha
 

ACADIA Pharmaceuticals Inc. (ACAD)

- NASDAQ
  • Aug. 7, 2013, 10:19 AM
    • Sentiment turns sour on Acadia Pharmaceuticals (ACAD -4.7%) following Tuesday's Q2 report.
    • Undeterred is Needham's Alan Carr who lifts his price target on the shares to $26 (from $16) citing a likely H2 2015 approval for pimavanserin in Parkinson's Disease Psychosis.
    | 1 Comment
  • Aug. 7, 2013, 12:49 AM
    • ACADIA (ACAD): Q2 EPS of -$0.11 misses by $0.02.
    • Revenue of $451K beats by $1K (PR)
    | Comment!
  • Jun. 18, 2013, 9:31 AM
    Acadia Pharmaceuticals (ACAD +0.4%) says data from a Phase III trial of pimavanserin suggest the treatment is well-tolerated and effective when administered long-term. (See also: JMP, SA contributor weigh in on ACAD)
    | 1 Comment
  • Jun. 14, 2013, 9:52 AM
    JMP (Outperform) boosts its price target on Acadia Pharmaceuticals (ACAD +3.2%) to $27 from $16. SA contributor PTSD Trader recently said pimavanserin is the "silver lining in the company's playbook."
    | Comment!
  • Jun. 14, 2013, 9:19 AM
    Premarket gainers: RH +13%. PXLW +11%. GRPN +8%. SCTY +8%. SYRG +6%. INVN +6%. ACAD +6%. SWHC +5%.
    Losers: CEMP -14%. AMSC -9%. HIMX -7%. CLSN -5%.
    | Comment!
  • Jun. 10, 2013, 12:45 PM
    Midday top 10 gainers: SGOC +25%. ACAD +17%. STEL +17%. MPAA +14%. TRMD +9%. OVAS +13%. CLIR +13%. TPLM +12%. RVLT +13%. KNDI +12%.
    Midday top 10 Losers: DVAX -35%. OSH -18%. ECTE -16%. AFFY -14%. AEPI -14%. OMX -12%. SHI -12%. PLM -11%. GNRC -11%. CBAK -11%.
    | 1 Comment
  • May. 14, 2013, 4:14 PM
    Acadia Pharmaceuticals (ACAD) announces a public offering. Size and terms of the offering weren't disclosed. Jefferies and Cowen are acting as the joint book-running managers for the offering. Shares -5% AH.
    | Comment!
  • May. 7, 2013, 8:05 PM
    ACADIA (ACAD): Q1 EPS of -$0.08 in-line. Revenue of $417K misses by $33K. (PR)
    | Comment!
  • Apr. 22, 2013, 11:17 AM
    Acadia Pharmaceuticals (ACAD +8.1%) spikes higher this morning, breaking out of a technical range on no specific news. The stock has been considerably volatile over the past month, having risen over 700% since November of last year on the back of strong results from its Parkinson's drug Pimavanserin.
    | Comment!
  • Apr. 14, 2013, 8:25 AM
    The reconstitution of the Russell indexes coming up in June, Credit Suisse aims to anticipate who's in and who's out. The rules-based approach of the Russell 2000 has allowed arbitragers to profit each summer by front-running the moves, making the Russell 2000 ETF (IWM) a poorer play for small cap fans than IJR . Expected among the top 25 adds are ARCP, SRPT, PBYI, ACAD, and WSTC. Among the top 25 deletes: CPST, FCEL, CHKE, OMER, and EML.
    | 1 Comment
  • Apr. 11, 2013, 12:49 PM
    Midday top 10 gainers: ACAD +55%. RNIN +26%. RAD +18%. ZUMZ +15%. MEA +13%. BIOL +12%. MGT +12%. PBTH +12%. MPAC +11%. TVL +11%.
    Midday top 10 losers: LEDS -17%. FTNT -14%. ROYL -14%. NTIC -16%. HXM -11%. CREG -11%. PRMW -10%. GNVC -10%. SGYP -10%. OCZ -10%.
    | Comment!
  • Apr. 11, 2013, 9:10 AM
    Premarket gainers: ACAD +43%. AMRS +15%. STEM +12%. RAD +12%. AEZS +11%. BYD +7%. BDSI +6%.
    Losers: FTNT -18%. AFFY -10%. SGYP -10%. HPQ -6%.
    | Comment!
  • Apr. 11, 2013, 8:05 AM
    Acadia Pharmaceuticals (ACAD) soars 51% after saying that the results of a Phase III trial of its Pimavanserin drug, plus other data, are enough for the company to file an application for FDA approval. Acadia will not now conduct a confirmatory phase III trial that was due to start this month. Pimavanserin is designed to treat Parkinson's disease psychosis. (PR)
    | 4 Comments
  • Mar. 25, 2013, 12:17 PM
    Acadia Pharmaceuticals (ACAD +10.1%) gets a big bump on a notable mention from Jim Cramer last Friday CNBC's on Mad Money. "This is the real deal," He says. "There was some profit taking this week, but you should hold onto it. ACAD is a fantastic spec." Additionally, Seeking Alpha contributor Brian Nichols added his two cents as well, calling the stock the safest bet in the biotech space right now after Pimavanserin's encouraging Phase 3 trial results.
    | 1 Comment
  • Mar. 21, 2013, 3:43 PM
    Acadia Pharmaceuticals (ACAD) continues to soar, now up over 27% after saying its drug candidate Pimavanserin worked very well reducing hallucinations and delusions related to Parkinson's Disease during Phase III testing.
    | 1 Comment
  • Mar. 21, 2013, 12:57 PM
    Midday top 10 gainers: ACAD +29%. CMT +19%. EGLE +17%. ANAC +17%. DRAM +18%. HNR +14%. ECT +14%. AFFY +13%. NICK +13%. GNK +12%.
    Midday top 10 losers: GMO -18%. BLDP -18%. AMBT -15%. SCHL -15%. CIMT -13%. AQ -13%. CHRM -12%. VTNR -11%. PSUN -10%. CSUN -9%.
    | Comment!
Visit Seeking Alpha's
ACAD vs. ETF Alternatives
Company Description
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Sector: Healthcare
Industry: Biotechnology
Country: United States